3/17
10:13 am
arct
Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Medium
Report
Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
3/8
12:25 pm
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/8
11:10 am
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "outperform" rating re-affirmed by analysts at William Blair.
3/7
11:14 pm
arct
Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments [Yahoo! Finance]
Low
Report
Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments [Yahoo! Finance]
3/7
04:09 pm
arct
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress [Yahoo! Finance]
Low
Report
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress [Yahoo! Finance]
3/7
04:01 pm
arct
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
Low
Report
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
3/4
02:56 pm
arct
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why [Yahoo! Finance]
Low
Report
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why [Yahoo! Finance]
2/26
09:00 am
arct
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
High
Report
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
2/22
08:30 am
arct
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
Medium
Report
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
2/20
09:00 am
arct
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
Low
Report
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
2/8
11:43 am
arct
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target raised by analysts at Citigroup Inc. from $40.00 to $48.00. They now have a "buy" rating on the stock.
Low
Report
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target raised by analysts at Citigroup Inc. from $40.00 to $48.00. They now have a "buy" rating on the stock.
2/5
08:45 am
arct
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster [Yahoo! Finance]
Low
Report
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster [Yahoo! Finance]
2/5
08:30 am
arct
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Low
Report
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
2/5
08:30 am
arct
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Low
Report
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
1/5
01:18 pm
arct
PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems [Yahoo! Finance]
Low
Report
PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems [Yahoo! Finance]
1/5
01:17 pm
arct
PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems
Low
Report
PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems
12/21
08:05 am
arct
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster [Yahoo! Finance]
Low
Report
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster [Yahoo! Finance]
12/21
08:00 am
arct
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Low
Report
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
12/21
08:00 am
arct
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Low
Report
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster